iiinova — where your digital self keeps evolving

Absea Biotech @abseabio.bsky.social · 06/10/2026

#HUPO2026 is a wrap. Five days in Singapore, many conversations with the proteomics community about their work, current challenges and where proteomics is heading. Thank you to everyone who stopped by Booth 227 and exchanged ideas with the team. #Proteomics #MassSpectrometry

000

Absea Biotech @abseabio.bsky.social · 30/09/2026

Abby made it to #HUPO2026 And of course, Abby is already getting some attention at Booth 227. Some of you have already stopped by looking for one. Good news: we still have a few Abbys with us. So if you’re still at HUPO, you might leave with more than just brochures and flyers. 👀 #Proteomics

000

Absea Biotech @abseabio.bsky.social · 29/09/2026

A few days into #HUPO2026 It’s been great to see familiar faces, meet new ones and hear what people are working on. We’re still at Booth 227 until Thursday. Come find us if you’re at HUPO 👋 #Proteomics #MassSpectrometry

010

Absea Biotech @abseabio.bsky.social · 28/09/2026

Today at #HUPO026. Ying Zhu will present our latest work on high-throughput crosslinking-MS and large-scale interactome analysis from intact human cells. Poster PS01.194 2:00 PM – 3:00 PM #Proteomics #teammassspec

000

Absea Biotech @abseabio.bsky.social · 27/09/2026

HUPO 2026 starts today! 🇸🇬 Clement, Ying and Phoebe are in Singapore and ready for a few days of conversations around proteins, antibodies and mass spectrometry. N-15 labeled proteins, Architectomics™, P2P2P™ and HybrMax™ are all part of the conversation. Come find us at Booth 227 👋 #HUPO2026

100

Absea Biotech @abseabio.bsky.social · 25/09/2026

Antibody and MS assays can study the same protein, but they answer different questions. Antibodies offer sensitivity, throughput and epitope-specific recognition. MS gives peptide-level information. So why should quantitative MS rely on a single peptide as its reference? #Proteomics

100

Absea Biotech @abseabio.bsky.social · 24/09/2026

How far can human interactome analysis be pushed in 24 hours? Ying Zhu will share our latest work at #HUPO2026 on high-throughput crosslinking-MS workflows and large-scale interactome analysis from intact human cells. Poster PS01.194 Monday | 2:00 PM – 3:00 PM Booth #227 See you soon!

000

Absea Biotech @abseabio.bsky.social · 22/09/2026

We’re heading to HUPO 2026 in Singapore 🇸🇬 We’ll be at Booth 227 from Sept. 27–Oct. 1, sharing some of the work we’ve been doing around proteins, antibodies and mass spectrometry. If you’re coming to HUPO, come find us. We’d love to meet you and hear what you’re working on. More info👇 #HUPO2026

110

Absea Biotech @abseabio.bsky.social · 18/09/2026

Our SVP Philip Lössl joined an AI in Biotechnology panel at Berlin yesterday, good conversation on where AI might actually helps. Two things we work on speak to that: SIEVE® (making molecules) and Architectomics® (mapping molecules, helping fill data gaps for models). DM us for more informations!

000

Absea Biotech @abseabio.bsky.social · 16/09/2026

pTau217 is a core AD blood #biomarker. What can other tau phosphorylation sites add? Brain-tissue studies suggest pSer396 rises mainly at later Braak stages, alongside more widespread cortical tau pathology. Absea’s #pTau396 pairs are evaluated using protein standards and biological samples. 🧪

000

Absea Biotech @abseabio.bsky.social · 08/09/2026

In plasma, pTau199 shows a distinct profile from pTau181 and pTau217. Autopsy data link plasma pTau199 to lower brain weight and shorter survival in AD-predominant cases. Absea pairs are assessed in protein standards and biological samples. 👇 #pTau199

000

Absea Biotech @abseabio.bsky.social · 03/09/2026

Interesting paper in npj Parkinson’s Disease: the researchers compared the same biomarkers in serum and extracellular vesicles across Parkinson’s, PSP and MSA. The EV measurements generally showed stronger discrimination than the matched serum measurements. #ParkinsonsDisease #Biomarkers

100

Absea Biotech @abseabio.bsky.social · 01/09/2026

APOE ε4 status now informs ARIA-risk discussions for anti-amyloid therapy. But ApoE4 protein-assay development remains challenging: the isoforms differ by just one amino acid, and biological matrices are complex. Our P2P2P workflow: recombinant protein → biological samples. 🧪 #APOE4 #Biomarkers

000

Absea Biotech @abseabio.bsky.social · 27/08/2026

A promising biomarker in discovery is one thing. Quantifying it in validation is another. Once you need a concentration, what is it based on? A good full-length reference isn't always easy to find. ¹⁵N-labeled proteins provide a distinguishable one — part of the library we're working on at Absea.

100

Absea Biotech @abseabio.bsky.social · 25/08/2026

A positive ELISA only tells you a clone binds the target. Not whether it'll work in WB, IHC, or flow. HybrMax™ tests application fit on hybridoma supernatant early, before expression, while sequencing runs in parallel.

100

Absea Biotech @abseabio.bsky.social · 20/08/2026

📢Publication highlight: Maslinic acid increased autophagy and ferroptosis in MDA-MB-231 cells. NCOA4 knockdown → less FTH1 degradation → weaker ferroptotic response. A link between ferritinophagy and ferroptosis. Absea anti-FTH1 & anti-SLC7A11 antibodies were used. DOI ↓ doi.org/10.21037/tcr...

doi.org

NCOA4-driven ferritinophagy and GSH reprogramming underlie maslinic acid-induced ferroptosis and autophagy in breast cancer

000

Absea Biotech @abseabio.bsky.social · 18/08/2026

Planning a protein–protein or protein–ligand interaction study? Architectomics™ maps binding partners, interfaces, and on- and off-target affinities across the proteome—in one experiment. Answer a few questions for a tailored plan and cost estimate, free and without obligation ↓

absea.bio

Absea | Digital Quotation Experience

000

Absea Biotech @abseabio.bsky.social · 11/08/2026

Detecting low-abundance CCL17 can make antibody-pair performance critical for immunoassay development Our ES-5482 just showed clear antigen-dependent signal, low background, and a concentration-dependent response by flow cytometry. Working on a CCL17 assay? See our validation data ↓

100

Absea Biotech @abseabio.bsky.social · 04/08/2026

Can immunotherapy make tumors more resistant? A new Immunity study identifies the ATP–P2RY2–PGE₂ axis as one mechanism of adaptive resistance to immunotherapy. The researchers used Absea's Cas9-GFP reagent as part of their CRISPR editing workflow. ↓ Paper + DOI 10.1016/j.immuni.2026.06.006

000

Absea Biotech @abseabio.bsky.social · 28/07/2026

An ADC PK result looks off — biology, or the assay? Peptide standards added after digestion can't report earlier variability. A standard can only tell you about the steps it actually went through. That's the principle behind the ¹⁵N-labeled standards we're developing at Absea. #ADC #MassSpec

001

Absea Biotech @abseabio.bsky.social · 21/07/2026

pTau217 works well as an Alzheimer's blood biomarker. So why look at pTau212? Studies suggest similar performance, but separating it from pTau217 without cross-reactivity is the assay challenge. pTau212 is now part of our tau portfolio, covering 50+ phosphorylation sites. ↓ Paper + product

100

Absea Biotech @abseabio.bsky.social · 09/07/2026

A new immune evasion regulator in liver cancer — STK40. Its loss combined with anti-PD-1 led to complete tumor regression in preclinical models. Absea's anti-STK40 antibody supported validation throughout. Zhu et al., Cancer Cell 2026. ↓link in comment #Immunotherapy #CancerResearch #Oncology

110

Absea Biotech @abseabio.bsky.social · 07/07/2026

June was a busy month. From conferences and scientific discussions to ongoing R&D, June kept us moving. We rounded it off with our annual team event on the Spandauer See. Thanks to everyone we met at ASMS, bio:cap Berlin, Drug Discovery Europe and the HRMS Symposium! #biotech #teammassspec

010

Absea Biotech @abseabio.bsky.social · 02/07/2026

Ultra-sensitive protein detection isn't only about sensitivity. It's about controlling background. A recent PRIPA study reached 0.024 pg/mL detection of p-tau181 and used Absea GFAP and NfL reagents in its multiplex assay development. ↓ #Neurodegeneration #Biomarkers

100

Absea Biotech @abseabio.bsky.social · 30/06/2026

Protein quantification often relies on one reference peptide, even though different peptides from the same protein yield different quantities. This doesn't necessarily mean something went wrong — part of your peptide population may carry a PTM or mutation. Which peptide are you trusting, and why?👇

200

Absea Biotech @abseabio.bsky.social · 25/06/2026

A tumor that stops showing its ID can evade the immune system. MHC-I downregulation reduces antigen presentation and helps tumors escape CD8+ T cells. The challenge is seeing where it happens. #IHC preserves tissue architecture, which is why we've invested in HLA and B2M antibodies for FFPE tissue.

100

Absea Biotech @abseabio.bsky.social · 23/06/2026

Longevity is not always about reducing oxidative stress. A new MDPI study suggests that paederoside (PSG) extends lifespan in C. elegans by promoting DAF-2/IGF1R degradation and activating DAF-16/FOXO and SKN-1/NRF2 signaling. The study used AKT3 and pAKT antibodies from Absea. #Aging #Longevity

100

Absea Biotech @abseabio.bsky.social · 18/06/2026

What happens to an #antibody after it leaves our lab? For the ones we contribute to @proteinatlas.bsky.social, the results are public. Every reagent goes through independent evaluation, with validation data openly available to the research community. #Proteomics

000

Reposted by Absea Biotech

Human Protein Atlas @proteinatlas.bsky.social · 13/05/2026

The Human Protein Atlas welcomes GeneTex’s recent announcement formalizing a collaborative relationship with the Human Protein Atlas. Collaborations with Atlas Antibodies, NCI-CPTC, Thermo Fisher Scientific, and Absea Biotech are also acknowledged. www.proteinatlas.org/news/2026-05...

121

Absea Biotech @abseabio.bsky.social · 16/06/2026

Better biomarkers are not about stronger signals but about the right signals. BD pTau217 selects brain-derived tau before measuring T217 phosphorylation—reducing the intermediate “gray zone” to 7%. An example of why antibody pair design matters and the idea behind our P2P2P workflow. #Alzheimers

010

Absea Biotech @abseabio.bsky.social · 12/06/2026

Our SVP Philip Lössl will be attending Drug Discovery Europe 2026 in Berlin next week. If you'd like to discuss proteomics, endogenous protein capture, interactomics, or assay development, feel free to get in touch. #DrugDiscoveryEurope #Proteomics

010

Absea Biotech @abseabio.bsky.social · 11/06/2026

MAU2 now has stronger CdLS support in a larger cohort. This new @natcomms.nature.com study reports 18 individuals, two mechanisms, and MAU2-specific methylation signatures. The Western blot work used our NIPBL antibody KT54. DOI: 👇 #Genetics

100

Absea Biotech @abseabio.bsky.social · 10/06/2026

A day into bio:cap Europe in Berlin. Philip Lössl and Phoebe Wei are spending the week meeting partners and and taking part in discussions across the life sciences community. Still a little time left before the conference wraps up. #biocapeurope #biocap26 #proteomics

000

Absea Biotech @abseabio.bsky.social · 09/06/2026

May. P2P2P (Pair → Pair → Product) introduced. Most of the month spent testing, refining, and moving projects forward. One evening, the team stepped outside the lab for a BBQ — might have started a new tradition in the process. #Biotech #LifeSciences #Berlin

010

Absea Biotech @abseabio.bsky.social · 08/06/2026

#ASMS2026 has come to an end. It was a great few days in San Diego with discussions around crosslinking-MS, interactomics, quantitative proteomics, and IP-MS workflows, and interest around Clement Potel’s poster. Thank you to everyone who stopped by Booth #1022 and connected with the team!

010

Absea Biotech @abseabio.bsky.social · 05/06/2026

We'll be at bio:cap in Berlin, June 9–11. Philip Lössl and Phoebe Wei attending — quantitative proteomics, interactomics, assay development on the agenda. The best conversations usually happen between sessions. Come find us. #biocapeurope #biocap26 #proteomics

000

Absea Biotech @abseabio.bsky.social · 04/06/2026

Last day at #ASMS 2026. It’s been a great week of discussions around crosslinking-MS, interactomics, quantitative proteomics, and IP-MS workflows in San Diego. The team is still at Booth #1022 today if you’d like to stop by one last time before the conference wraps up. #teammassspec #proteomics

010

Absea Biotech @abseabio.bsky.social · 03/06/2026

Crosslinking-MS, interactomics, quantitative proteomics… and apparently Abby, our mascot. Some traditions seem to follow us to every conference, and ASMS 2026 has been no exception. Stop by Booth #1022 this week and you might leave with a smaller one too. #ASMS2026 #teammassspec

020

Absea Biotech @abseabio.bsky.social · 02/06/2026

Today at #ASMS2026. Clément Potel will present our latest work on high-throughput crosslinking-MS and large-scale interactome analysis from intact human cells. Poster TP079 10:30 AM – 2:30 PM #Proteomics #teammassspec

010

Absea Biotech @abseabio.bsky.social · 31/05/2026

#ASMS2026 is underway. Tao Chen, Philip Lössl, and Clément Potel are in San Diego this week discussing interactomics, quantitative proteomics, and crosslinking-MS workflows. Come say hello at Booth #1022. Poster TP079 on Tuesday. #teammassspec #proteomics

010

Absea Biotech @abseabio.bsky.social · 28/05/2026

How far can human interactome analysis be pushed in 24 hours? Clément Potel will share our latest work at #ASMS2026 on high-throughput crosslinking-MS workflows and large-scale interactome analysis from intact human cells. Poster TP079 Tuesday | 10:30 AM – 2:30 PM Booth #1022 See you soon!

110

Absea Biotech @abseabio.bsky.social · 26/05/2026

LC–MS variability is less often the main limitation in proteomics, but inter-lab reproducibility still breaks more than expected. Peptide standards miss upstream variability. ¹⁵N protein standards at Absea follow the full workflow. Where do you see most variability? #teammassspec #proteomics

000

Absea Biotech @abseabio.bsky.social · 21/05/2026

We’ll be at #ASMS2026 in San Diego (May 31–June 4). Clement Potel, Philip Lössl, and Tao Chen will be there at booth #1022. Happy to talk proteome-scale protein resources, N-15 workflows, IP-MS reagents, P2P2P antibody development, and related workflows. #teammassspec #biotech

010

Absea Biotech @abseabio.bsky.social · 19/05/2026

Screening #antibodypairs in both recombinant #protein and cell lysate early changes what moves forward. Pairs that only work in ideal conditions drop out sooner. Especially when you're seeing unstable signals or low separation in plasma. That’s how we structure it with P2P2P.

000

Absea Biotech @abseabio.bsky.social · 14/05/2026

Why does an antibody pair work in screening— then fail in plasma? Three reasons. 👇️ 1/5

100

Absea Biotech @abseabio.bsky.social · 12/05/2026

#Antibodypairs look strong in screening. Then real samples behave differently. Usually not an antibody issue. It’s the screening conditions. If you're dealing with unstable signals or high background, this is usually where it starts. That’s the gap we work on with P2P2P. #Biotech

000

Absea Biotech @abseabio.bsky.social · 07/05/2026

#Spatialbiology is shifting—from mapping cells to what they’re doing locally. In #immunology, that means cytokines: low-abundance, highly local, hard to measure. A real bottleneck. We built a pool of 128 IHC-validated antibodies to make cytokine detection in tissue less of a guessing game.

010

Absea Biotech @abseabio.bsky.social · 05/05/2026

April. Analytica, German Biotech Days, AACR — three conferences, lots of conversations and perspectives. Back in the lab, MS running steadily and a new HPLC for peptide fractionation. A steady month overall, with work moving forward. Team dinner to wrap it up. #Biotech #LifeSciences #Proteomics

020

Absea Biotech @abseabio.bsky.social · 30/04/2026

Same protein. Same sample. Different peptides can give different quantitative results. QC studies report ~38–56% differences between signature peptides under peptide-level calibration. Do you see this in your workflows?👇

100

Absea Biotech @abseabio.bsky.social · 28/04/2026

Going to #ALDA in Boston this week. Lots of interesting conversations happening around #proteomics right now. Less about instrument and more about access, scale, and data. Our CEO and SVP, Tao Chen and Philip Lossl, will be there. If you’re attending, feel free to reach out.

010